BAYLOR COLLEGE OF MEDICINE

Sunil Gupta, MD, joins Nanoscope Therapeutics Inc.'s Board of Directors. Gupta, a retinal surgeon and entrepreneur, brings expertise in drug development and medical devices. Nanoscope CEO Sulagna Bhattacharya praises Gupta's accomplishments in treating inherited retinal diseases and dry age-related macular degeneration. Gupta expresses excitement about Nanoscope's gene therapies for retinitis pigmentosa and Stargardt, highlighting the company's progress towards commercialization.

Expert from Baylor College of Medicine offers tips for holiday eating while on GLP-1 medications, emphasizing small portions, nutrient-dense diet, and hydration to maintain weight loss and diabetes control.

The Southwest Forum on Difficult to Treat Depression, chaired by Jordan F. Karp, MD, convened experts to discuss novel mechanisms, evidence-informed algorithms, and access to comprehensive depression care. Topics included advanced treatments like brain stimulation and neurosteroids, challenges in late-life depression, digital mental health treatments, and the role of biomarkers in precision psychiatry. The forum emphasized the need for equitable access and personalized medicine to improve outcomes in treatment-resistant depression.

Eisbach Bio relocates to Houston with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas to develop EIS-12656, a cancer therapy targeting HRD tumors. The grant supports Phase 2 trials at MD Anderson Cancer Center, positioning Texas as a hub for innovative cancer treatments.

Dr. Brendan Lee's lab developed an adenovirus gene therapy for osteoarthritis, showing promising results in Phase 1 clinical trials. The therapy, PCRX-201, received FDA's RMAT designation and demonstrated sustained improvements in knee pain, stiffness, and function.

Baylor College of Medicine and The Texas Heart Institute form a cardiovascular health and research center, to be led by Dr. Joseph G. Rogers, aiming to elevate patient care, accelerate research, and bolster education. The integration, known as The Texas Heart Institute at Baylor College of Medicine, will be based at Baylor St. Luke’s Medical Center, with a plan to raise funds for full integration within five years.

Baylor College of Medicine appointed nine new members to its Board of Advisors, including John Damonti, Carlos de Aldecoa, Jr., Bradley Freels, José Ivo, Charles Lawrence, Jr., Mike Loya, Gina Luna, Deviyani Misra-Godwin, and Fred Seigel. The Board works with the College’s Board of Trustees to support its strategic needs and mission.

St. Baldrick's Foundation announces $1.2 million in infrastructure grants for pediatric cancer clinical trials, aiming to increase participation and offer new hope to children with cancer. Kathleen Ruddy, CEO, emphasizes support for communities impacted by hurricanes. Additionally, a research grant from 'Jack's Pack – We Still Have His Back' funds Dr. Roarke Kamber's Burkitt's Lymphoma research at UCSF. Grants awarded to various institutions across the U.S.

Greenwich LifeSciences updates on 2024 events, including conferences and sponsorships, and details its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy targeting HER2+ breast cancer recurrence.

Dr. Maya Balakrishnan explains distinguishing between heartburn and heart conditions, noting age-related risks and symptoms, and emphasizing the importance of consulting a doctor for persistent chest pain.